Adalvo is pleased to announce the successful Pivotal BE Study for Riociguat 2.5mg Film Coated Tablets.
Our product is being developed in collaboration with one of our strategic partners, based on the reference brand Adempas and is indicated in the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
The brand sold approximately $323M globally in 2022 with Global 3Y CAGR at 4%, according to IQVIA.
With our clearly defined product pathway, we believe Adalvo will be amongst the first wave of filers, and first to launch in all major markets.
Adalvo is working on several interesting Cardiovascular projects, as depicted below, further highlighting our ability to offer differentiated, value-added dossiers to our partners.
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
margarida.neves@adalvo.com – Brazil
marta.puig@adalvo.com - LATAM (exc. Brazil) & South Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
arni.baldursson@adalvo.com - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force